carbidopa has been researched along with Adverse Drug Event in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Bahroo, L; Di Maria, G; Jankovic, J; Lamotte, G; Lenka, A | 1 |
| Baille, G; Blaise, AS; Carrière, N; Defebvre, L; Devos, D; Dujardin, K; Grolez, G; Kreisler, A; Kyheng, M; Moreau, C; Mutez, E; Seguy, D | 1 |
| Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y | 1 |
| Farbman, ES; Hauser, RA; Klingler, M; Lee, A; LeWitt, PA; Oh, C; Qian, J; Rudzińska, M; Waters, CH | 1 |
| Arbelo, JM; Catalán, MIJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O | 1 |
1 review(s) available for carbidopa and Adverse Drug Event
| Article | Year |
|---|---|
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2022 |
2 trial(s) available for carbidopa and Adverse Drug Event
| Article | Year |
|---|---|
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease.
Topics: Administration, Inhalation; Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Powders; Single-Blind Method; Spirometry | 2020 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
6 other study(ies) available for carbidopa and Adverse Drug Event
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endoscopy, Gastrointestinal; Female; France; Gastrostomy; Gels; Humans; Infusion Pumps; Intestinal Absorption; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey | 2021 |
Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2019 |